Chronic pain costs the US approximately $650 billion annually, and most chronic noncancer pain remains inadequately treated. In the absence of suitable chronic pain treatment (analgesic) alternatives, an epidemic of opioid overuse, dependence, abuse, diversion, and life-threatening complications has occurred.
Various sources estimate that the knee osteoarthritis segment of the global osteoarthritis therapeutics market is expected to grow from $5.9 billion in 2021 to $9.0 billion in 2026 at a CAGR of 8.8% for the forecast period of 2021 to 2026.
Erythromelalgia (Orphan Indication)
Erythromelalgia (EM) is a rare condition that primarily affects the feet and, less commonly, the hands (extremities). It is characterized by intense, burning pain of affected extremities, severe redness (erythema), and increased skin temperature that may be episodic or almost continuous in nature. Although erythromelalgia typically affects both sides of the body (bilateral), it may sometimes involve only one side (unilateral). The disease course may be extremely variable from case to case. Currently, there are no approved therapies for EM.
The overall age and sex-adjusted incidence rate per 100,000 people per year in a population-based study in the US was 1.3. Researchers in Norway have estimated an incidence of 0.25 per 100,000 and a prevalence of 2 per 100,000 in Norway. (Incidence refers to the number of new cases of a particular condition during a specific period, while prevalence indicates the total of new and old cases of a condition at any one time.) We estimate the incidence rate in the US only is between 4,000 to 6,000 patients per year with the prevalence of approximately 45,000 patients assessing the market opportunity to be roughly $500 million per year.